stonks4u
Sign up free
FULC logo

FULC Fulcrum Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$3.74
+0.03 (+0.81%)

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered feta…

Market Cap: $285.35Mwww.fulcrumtx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

90
90
Aug 10Aug 14

Quote

Day Range
$3.65 – $3.75
52-Week Range
$2.83 – $15.74
Volume
$978.8K
Market Cap
$285.35M
50-Day Avg
$3.66
200-Day Avg
$7.68
Prev Close
$3.71
Open
$3.65

Valuation & Ratios

P/E Ratio
-9.58
EPS
$-1.18
P/B Ratio
2.05
P/S Ratio
0.00
Debt/Equity
0.02
Current Ratio
27.40
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-21.5%
Return on Assets
-20.4%
FCF Yield
-8.4%
EV/EBITDA
-7.15

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-74.88M$-1.18
2024$80.00M$-9.72M$-0.16
2023$2.81M$-97.33M$-1.59
2022$6.34M$-109.87M$-2.35
2021$19.16M$-80.85M$-2.22

Social Signal Score

41
5d
41
2 mentions
—
30d
41
3 mentions
—
60d
41
3 mentions
—
90d
41
3 mentions
—
news: 3

Earnings

Thu, Oct 29(in 2 months)

Consensus estimate $-0.13 per share

5of 7 quarters beat consensus

Typical surprise +3.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Jul 30$-0.21 vs $-0.24beat
  • Mon, Apr 27$-0.25 vs $-0.31beat
  • Tue, Feb 24$-0.31 vs $-0.31beat
  • Wed, Oct 29$-0.31 vs $-0.29miss
  • Tue, Jul 29$-0.28 vs $-0.29beat
  • Thu, May 1$-0.28 vs $-0.29beat

Estimates and results for FULC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

FULChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsnewsfilecorp.com·1d ago·Negative

    Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have informa…

    View source ↗
  • Newsnewsfilecorp.com·3d ago·Negative

    Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors for Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 12, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have

    View source ↗
  • Newsnewsfilecorp.com·5d ago·Negative

    Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors Who Suffered Losses to Contact the Firm New York, New York--(Newsfile Corp. - August 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you hav

    View source ↗